Histological outcome in patients with chronic hepatitis C given a 60‐week interferon alfa‐2b treatment course

Reichard, Olle; Glaumann, Hans; Norkrans, Gunnar; Wejstål, Rune; Frydén, Aril; Schvarcz, Robert; Weiland, Ola

doi:10.1111/j.1600-0676.1994.tb00070.x

Cited by 18 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From a theoretical perspective, inflammatory markers may be better candidates for predicting fatigue than disease severity measures. Pro-inflammatory cytokines induce fatigue in acute and chronic infections or when they are administered to treat infections, as for example interferon treatment does in hepatitis C infection (Reichard et al, 1998;Zeuzem, et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

Fatigue in chronic hepatitis C infection a mixed method study

Zalai¹

2021

Preprint

View full text Add to dashboard Cite

Fatigue is a main patient reported outcome of chronic hepatitis C (HCV) infection; yet its contributors are unknown. Objectives: The study (1) evaluated fatigue predictors, (2) tested the mediating role of fatigue cognitions, (3) screened for sleep disorders, and (4) explored fatigue from patients’ perspectives. Participants: Both sexes (age>18 years, N = 115) with chronic HCV infection. Design: Cross-sectional. Results: Sixty percent reported severe fatigue (FSS≥4). Fatigue perceptions were the main predictors of fatigue (ß=.58, bias corrected CI = .070-.163). Fatigue perceptions mediated the relationship between comorbidities and fatigue. Half of the sample reported clinically significant symptoms of insomnia and/or sleep apnea. Eight main fatigue themes were endorsed by the participants. Conclusions: Fatigue and sleep disorders were clinically significant issues. Fatigue cognitions may contribute to severe fatigue outcomes. Significance: Integrating the findings into existing sleep and fatigue treatments could improve clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Fatigue in chronic hepatitis C infection a mixed method study

Zalai¹

2021

Preprint

View full text Add to dashboard Cite

show abstract

Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment

et al. 1995

Self Cite

View full text Add to dashboard Cite

Fourteen patients with chronic hepatitis C who had a sustained response to a 60-week interferon alfa-2b treatment course were followed, biochemically and virologically, 2 years after treatment cessation. Biopsies were repeated in 12 of 14 for histological and virological evaluation at 2-year follow-up. All 14 patients had normal serum alanine transaminase (s-ALT) levels and were negative for hepatitis C virus (HCV) RNA in serum during treatment and at short-term follow-up 6 months post-treatment. At 2-year follow-up, 13 patients still had normal ALT levels (< 0.6 mukat/L for women; < 0.8 mukat/L for men), 1 a near normal level (0.76 mukat/L); all were HCV RNA negative in serum, and 11 of 12 also in the liver. Liver histology improved during treatment and remained stable during the 2-year follow-up. The authors conclude that most sustained responders, who have normal ALT levels and are nonviremic at short-term follow-up 6 months after interferon treatment, will continue to have a durable long-term response without relapse of the viremia.

show abstract

Combined treatment with interferon alpha‐2b and ribavirin for chronic hepatitis C in patients with a previous non‐response or non‐sustained response to interferon alone

Schvarcz

Yun

Sönnerborg

et al. 1995

Journal of Medical Virology

114

View full text Add to dashboard Cite

Ten patients with chronic hepatitis C, six of whom had not responded and four of whom had responded in a non-sustained fashion to interferon-alpha treatment alone, were given interferon alpha-2b and ribavirin in combination during 24 weeks. Interferon alpha-2b was given subcutaneously, at a dose of 3 MU thrice weekly, together with ribavirin orally, at a dose of 1,000-1,200 mg/day. All four patients with a prior non-sustained response to interferon alone had normal alanine aminotransferase (ALT) levels at the end of treatment as well as during follow-up (> or = 24 weeks post treatment). Furthermore, all four lost serum HCV-RNA at the end of treatment and three continued to be negative during follow-up. Among patients with a prior non-response to interferon alone three of six had normal ALT levels at the end of treatment and one at follow-up. Two of six became HCV-RNA negative at cessation of treatment, one of whom was negative also at follow-up. All former non-sustained responders and one of six non-responder patients thus showed a sustained biochemical response with eradication of HCV-RNA from serum in all cases but one. It is concluded that combination therapy with interferon alpha-2b and ribavirin offers a chance of sustained biochemical response with eradication of the viremia in patients who have not shown a persistent response to interferon-alpha alone.

show abstract

Histological outcome in patients with chronic hepatitis C given a 60‐week interferon alfa‐2b treatment course

Cited by 18 publications

References 18 publications

Fatigue in chronic hepatitis C infection a mixed method study

Fatigue in chronic hepatitis C infection a mixed method study

Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment

Combined treatment with interferon alpha‐2b and ribavirin for chronic hepatitis C in patients with a previous non‐response or non‐sustained response to interferon alone

Contact Info

Product

Resources

About